Research programme: stomatitis polyclonal antibody - Avaxia Biologics

Drug Profile

Research programme: stomatitis polyclonal antibody - Avaxia Biologics

Alternative Names: Mucositis polyclonal antibody - Avaxia Biologics

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avaxia Biologics
  • Class Polyclonal antibodies
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Stomatitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Stomatitis in USA (Topical)
  • 28 Jun 2010 Avaxia Biologics receives grant from the Massachusetts Life Sciences Center for antibody development in Stomatitis
  • 16 Sep 2009 Preclinical trials in Stomatitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top